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Background: Established heart failure in thalassaemia major has a poor prognosis and optimal management
remains unclear.
Methods: A 1 year prospective study comparing deferoxamine (DFO) monotherapy or when combined with
deferiprone (DFP) for patients with left ventricular ejection fraction (LVEF) <56% was conducted by the Thalassemia
Clinical Research Network (TCRN). All patients received DFO at 50–60 mg/kg 12–24 hr/day sc or iv 7 times weekly,
combined with either DFP 75 at mg/kg/day (combination arm) or placebo (DFO monotherapy arm). The primary
endpoint was the change in LVEF by CMR.
Results: Improvement in LVEF was significant in both study arms at 6 and 12 months (p = 0.04), normalizing
ventricular function in 9/16 evaluable patients. With combination therapy, the LVEF increased from 49.9% to 55.2%
(+5.3% p = 0.04; n = 10) at 6 months and to 58.3% at 12 months (+8.4% p = 0.04; n = 7). With DFO monotherapy,
the LVEF increased from 52.8% to 55.7% (+2.9% p = 0.04; n = 6) at 6 months and to 56.9% at 12 months (+4.1%
p = 0.04; n = 4). The LVEF trend did not reach statistical difference between study arms (p = 0.89). In 2 patients on
DFO monotherapy during the study and in 1 patient on combined therapy during follow up, heart failure
deteriorated fatally. The study was originally powered for 86 participants to determine a 5% difference in LVEF
improvement between treatments. The study was prematurely terminated due to slow recruitment and with the
achieved sample size of 20 patients there was 80% power to detect an 8.6% difference in EF, which was not
demonstrated. Myocardial T2* improved in both arms (combination +1.9 ± 1.6 ms p = 0.04; and DFO
monotherapy +1.9 ± 1.4 ms p = 0.04), but with no significant difference between treatments (p = 0.65). Liver iron
(p = 0.03) and ferritin (p < 0.001) both decreased significantly in only the combination group.
Conclusions: Both treatments significantly improved LVEF and myocardial T2*. Although this is the largest and
only randomized study in patients with LV decompensation, further prospective evaluation is needed to identify
optimal chelation management in these high-risk patients.
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Although cardiomyopathy from iron overload is becom-
ing less common in the early lives of Thalassemia Major
(TM) patients, particularly in cohorts born after sc DFO
became available from an early age [1], the terminal
event for older patients is often iron mediated cardiac
disease. Recent reviews highlight the paucity or lack of
controlled data comparing different chelation regimens
in the management of heart failure and other compli-
cations of iron overload [2,3].
Heart failure can sometimes be reversed with conti-
nuous DFO monotherapy [4-6] but does not always re-
spond even to intensive 24 h IV DFO monotherapy,
particularly in patients with severe cardiac iron loading
and T2* values <6 ms by cardiovascular magnetic reson-
ance (CMR) [6]. Several lines of evidence suggest that pa-
tients with mild to moderate heart iron and without heart
failure respond more effectively to regimes containing
DFP compared to DFO monotherapy [7-10]. In a
randomised study, mild to moderate myocardial iron (T2*
of 8–20 ms) improved more over 1 year with combined
DFO and DFP than with standard dose DFO 5 day/week
[8]; LVEF, while normal in all cases, also increased more
in the patients treated with combined therapy. An obser-
vational study also suggests that, when combined with
DFP, ‘standard’ discontinuous DFO can improve impaired
LV function in patients with T2* values <8 ms [9]. Studies
with deferasirox monotherapy, whilst showing clear im-
provements in myocardial T2*, have focused only on pa-
tients with LVEF ≥ 56% [11].
At the time that our study was designed (commencing
2005) and undertaken, DFP was not licensed in North
America and the investigators judged that a study compa-
ring established first line monotherapy with DFO with or
without the addition of DFP (combination) would be help-
ful in defining whether addition of DFP conferred further
benefit in this setting. In this study, physicians entering
patients sought to administer DFO at the maximum safe
doses commensurate with body iron loading for as many
hours daily as were achievable with addition of DFP (com-
bination arm) or placebo (DFO monotherapy arm).
Methods
Study design and aims
This was a 12 month Phase II, multi-site, group-
sequential, randomized, double-blind, placebo controlled
comparison of combination deferoxamine (DFO) and
deferiprone (DFP) vs DFO monotherapy (with placebo)
in transfusion-dependent adult TM patients with de-
creased left ventricular ejection fraction (LVEF). The
primary aim was to evaluate whether DFP and DFO
combination therapy produced greater improvement in
LVEF than with DFO monotherapy. The secondary aims
were: (1) To evaluate whether myocardial iron burden,as estimated by myocardial T2*, differed between these
treatments. (2) To compare changes in other measures
of iron overload such as ferritin and liver iron concen-
trations (LIC) between the two treatments. (3) To com-
pare safety markers of combined therapy with DFO
monotherapy.
Subcutaneous or intravenous DFO was administered
daily at 50–60 mg/kg for 12–24 hr/day 7 days/week. When
necessary, the DFO dose was adjusted downwards to take
account of falling (or low baseline) ferritin so as to mini-
mise the risk of audiometric and retinal toxicity or up-
wards at the clinician’s discretion for inadequate response.
In addition to this DFO regimen, DFP (75 mg/kg/day) or
placebo was administered orally in 3 divided doses and
timed so that 2 of 3 doses were contemporaneous with the
DFO infusion.
The inclusion criteria were: (1) ≥8 transfusions a year,
age ≥18 years and LVEF ≤56% by balanced steady state
free precession (SSFP) CMR, (2) baseline serum ferri-
tin >1000 μg/L or <1000 μg/L, confirmation of myo-
cardial iron loading by cardiac T2* <20 ms. Exclusion
criteria included: contraindication to CMR: severe congest-
ive heart failure (HF) (NYHA Classification IV): current
treatment for hepatitis: creatinine clearance <50 ml/min:
neutrophils <1.5 × 109/L or platelet count <80 × 109/L:
treatment with DFP or deferasirox during the previous
2 weeks or previous adverse experience to DFP: patients
unwilling to consider DFO at 50–60 mg/kg 12–24 hours
per day 7 days per week.
Participants were from the Thalassemia Clinical Re-
search Network (TCRN). Out of 190 initially contacted,
104 were screened, 30 were eligible, 22 agreed to ran-
domisation, and 20 were randomized and treatment ini-
tiated. Patients receiving treatment were from Toronto
(6), Boston (4), Oakland (4), Beirut (4), Chicago (1) and
New York (1). The study protocol was approved by the
TCRN Data and Safety Monitoring Board and by the
ethical review boards of all TCRN institutions. Written
informed consent was obtained from all participants.
An independent safety monitoring committee moni-
tored safety and progress of the trial. The trial ran be-
tween 2005 and 2008 when the study was terminated
due to slow patient accrual.Baseline evaluations
Blood for baseline central analysis of iron assays was
drawn before treatment initiation. Cardiac baseline mea-
surements were: Holter monitor, electrocardiogram (EKG),
echocardiogram, and 6-minute walk. Results from the
screening CMR were considered as baseline measure-
ments. Liver Iron Concentration (LIC) was performed by
liver R2 MRI [12], biopsy was performed in 1 patient and
SQUID biosusceptometry in 3 patients. Audiometry and
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before or within 14 days after study treatment initiation.
Randomization
Participants were randomized within 60 days of CMR
screening and assigned in a 1:1 ratio stratified by New
York Heart Association Classification. Randomization
and stratification was performed by ADEPT (the same
system we used for data entry) with a sequence using
permuted random blocks. This uses an algorithm for
randomization that allows specification of chosen parame-
ters, such as stratification and imbalance tolerance. The
parameters for randomization were specified in the proto-
col. The ADEPT algorithm maintains the imbalance at all
times, decreasing statistical problems resulting from stop-
ping the trial before completion. To maintain balance at
all sites, a maximum imbalance in allocation of 2 partici-
pants was permitted. Treatment was to be initiated within
72 hours of randomization and after completion of all
baseline data collection. Treating clinicians were blinded
to treatment allocations.
Follow-up schedule
On-treatment blood counts were performed every 7 days
and at each monthly study visit, which included an inter-
view for review of symptoms, compliance, concomitant
medications and transfusion data. Every 12 weeks, phys-
ical examinations, weight, and fasting chemistries were
performed. At 24 and 52 weeks, cardiac function by
CMR, cardiac T2* and liver R2 (= 1/T2) by MRI, 24-hr
Holter monitor, 6-minute walk, audiometry, and oph-
thalmology were performed. For participants with serum
ferritin <1000 μg/L, audiometry and ophthalmology were
performed at weeks 12 and 36 in addition to weeks 24
and 52. Participants for whom study medication was
suspended or permanently discontinued (due to serious
adverse events) continued to be seen every four weeks
following the normal schedule.
Methodology for LVEF and T2*
All CMR scans were performed at 1.5 T including
General Electric (Cornell, Children’s Hospital Boston,
Toronto General Hospital, Children’s Hospital Los
Angeles), Siemens (Children’s Hospital Philadelphia),
and Philips (Children’s Hospital Oakland, American Uni-
versity of Beirut) platforms. Cardiac T2* measurements
were collected using either a multiple-echo gradient
echo (General Electric and Siemens) or single-echo gra-
dient echo pulse sequence with 8 echoes collected be-
tween 2.2 and 18 ms. All sites were required to scan
manganese chloride phantom having R2* spanning
30-500 Hz (where R2* = 1/T2*), with good linearity with
respect to manganese concentration and good overall
R2* agreement (COV <10%). Cardiac volumes and ejec-tion fraction were derived from fifteen short axis steady-
state free precession images using the MASS software
package (Medis, The Netherlands). Cardiac T2* was de-
rived using validated techniques [13]. Some authors have
reported lower T2* values using this fitting algorithm
compared with a truncated exponential fit for T2* <5 ms
[14] but such differences observed in the core labora-
tory appear to be no greater than 15% even at T2*
below 1 ms [15]. CMR processing was performed at a
central core laboratory located at Children’s Hospital
Los Angeles.
Statistical analysis
The intended sample size of 86 patients (N = 43 per arm)
had 80% power to detect a 5% difference in LVEF between
the two arms after 1 year, assuming a standard deviation
of change in LVEF of 7.46%, and 20% loss to follow-up.
Variance estimates for the power analysis were based on
prior longitudinal studies of TM patients with cardiac dys-
function at University College London Hospitals (UCLH)
with planned interim updates to the required sample size
based on actual observed variance, using an information-
based group sequential trial design. For baseline differ-
ences, the t-test was used for continuous variables and the
fisher’s exact test was used for categorical variables to
compare two treatment groups at baseline. This paper
considers observed trends in the key data (LVEF, T2*, fer-
ritin, LIC) using the per protocol analysis. Linear mixed
models with fixed terms for treatment arm, time, and the
treatment x time interaction were used, allowing for ran-
dom participant-specific intercepts and slopes. Compound
symmetric covariance structure was assumed. These
mixed models provide unbiased estimates when data are
missing at random, conditional on the observed data and
model assumptions.
The study was stopped early by NHLBI when analysis
of the interim data confirmed a required sample size of
close to the original 86 that was not achievable within
the required time frame. The achieved sample size had
80% power to detect an 8.6% difference in LVEF. Al-
though the final study sample provides inadequate
power for the primary aim, it was considered valuable to
compare paired means of the primary and secondary
endpoints from the subset of subjects who completed
follow-up, as well as the safety measures at available
time points.
Results
Patient baseline data
Baseline patient characteristics including age, LVEF,
cardiac T2*, LIC, serum ferritin and 6 minute walk are
shown in Table 1. Baseline echo was also obtained in
DFO monotherapy (LVEF = 56.8 ±7.3%) and combina-
tion arms (LVEF = 54.7 ±5%) (p = 0.46).
Table 1 Baseline values for LVEF, myocardial T2*, LIC, ferritin and 6 minute walk
Patient Arm Age LVEF T2* LIC# Ferritin 6 minute
Sex % ms mg/g/dw μg/L Walk
Base Base Base Base Distance m
1a Comb 23, M 51.9 5.1 34.8 5893 526
2a Comb 30, F 49.9 5.9 4.7 2817 425
3a Comb 22, M 35.5 2.7 6.7 2961 nd
4a Comb 30, F 48.9 6.3 12.1 3637 nd
5a Comb 19, M 38.8 7.1 14.2 3054 nd
6a Comb 21, M 56.0 21.1 32.1 7125 445
7a Comb 28, M 55.3 12.3 5.3 1608 550
8a Comb 33, M 55.2 14.8 9.4 nd 567
9a Comb 34, M 53.0 10.0 2.9 1962 492
10a Comb 23, M 53.8 3.3 9.7 2800 389
11a Comb 28, F 55.4 3.9 7.4 735 359
Mean 26.40 51.8 8.4 12.7 3259.2 469.1
SD 5.2 5.7 10.8 1924.8 76.5
1b Mono 19, F 53.9 12.0 11.7 2623.0 nd
2b Mono 32, F 42.2 10.7 6.2 864.0 689
3b Mono 32, M 44.8 2.4 32.1 7394.0 nd
4b Mono 23, M 51.4 9.0 12.4 4649.0 600
5b Mono 37, M 46.7 8.3 2.7 2329.0 540
6b Mono 33, M 54.0 5.9 1.5 280.0 644
7b Mono 19,F 53.1 3.1 2.7 176.0 390
8b Mono 17, F 47.7 4.1 6.6 1220.0 287
9b Mono 20.F 54.9 5.7 12.4 nd nd
mean 25.80 49.9 6.8 9.8 2441.9 525.0
SD 4.6 3.4 9.4 2485.1 156.1
p comb 0.52 0.86 0.49 0.54 0.22 0.39
vs mono
Abbreviations: Comb (combination) = DFP + DFO. Mono (monotherapy) = DFO alone. SD = standard deviation of the mean.
# All liver iron measurements were by ferriscan except: arm A patient 5 and 6 arm B patient 4 where SQUID and ARM B patient 3 where liver biopsy
was performed.
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The starting dose of DFO and the route given are shown
in Table 2. Although the study protocol encouraged clini-
cians to use 24 h IV DFO where practical, only 1 patient in
the combination arm and 2 in the DFO monotherapy arm
received close to 24 h iv DFO throughout the study. Two
patients in the combination arm received 8–12 h IV DFO.
The remainder received sc DFO 7 nights a week at a mean
of 12.1 and 12.3 hours/night for combination and DFO
monotherapy arms respectively. This represents an in-
crease in duration compared with standard DFO therapy
of 8 h. The average DFO starting dose was similar with
combination (50 mg/kg) or DFO monotherapy (40 mg/kg).
Two patients received only low starting doses in the DFO
monotherapy arm <30 mg/kg because of low baselineferritin (280 and 176 μg/L) but these patients had T2 < 20*
confirmed before entering the study.
Study completion, dose modifications and AEs
Study accrual began in 2005. A total of 20 subjects had
been randomized at the time that the study was stopped
in 2008, 11 to the combination arm and 9 to the DFO
monotherapy arm. One in the DFO monotherapy arm
withdrew before initiating treatment. After early termin-
ation, each patient still on study was seen for one last
close-out visit, with collection of all 52 week measures,
including the primary outcome of CMR. If the subject
was within 12 weeks, then the final close-out visit was
treated as a 24 or 52 week visit for data analysis. Ten
patients completed at least close to 6 months with
Table 2 Last visit # values for LVEF, myocardial T2*, LIC ferritin and 6 minute walk
Patient Arm DFO DFO LVEF T2* LIC Ferritin 6 minute
Route Dose % ms mg/g dw μg/L Walk
hr/d mg/kg/d Final Final Final Final Distance m
1a Comb SC,12 52 56.0 5.7 27.7 3628 492
2a Comb SC,10 51 56.6 6.3 nd 2747 554
3a Comb IV, 24 59 39.2 3.1 4.0 1154 378
4a Comb SC,12 53 51.3 9.2 2.8 1811 516
5a Comb IV, 8 51 58.0 6.0 6.8 3008 352
6a Comb SC,12 50 61.1 20.8 16.1 4727 352
7a Comb IV, 12 46 59.6 19.2 2.9 343 550
8a Comb SC,13 40 nd nd nd nd na
9a Comb SC,14 44 61.6 20.8 2.1 622 475
10a Comb SC,12 50 54.6 3.9 7.7 1130 397
11a Comb SC,12 50 65.4 3.5 1.7 200 364
mean 12.9 49.6 56.3 9.8 8.0 1937.0 443
SD 5.0 7.2 7.4 8.7 1528.0 82.8
1b Mono SC, 10 49 50.9 11.3 14.6 4409 689
2b Mono SC,12 60 nd nd nd 439 na
3b Mono IV, 24 50 nd nd nd v high na
4b Mono IV, 24 41 53.3 9.4 13.8 2540 590
5b Mono SC,14 30 51.6 12.8 1.3 890 563
6b Mono SC,14 23 66.9 9.9 2.1 413 578
7b Mono SC,12 8 49.6 3.3 3.3 152 410
8b Mono SC,12 50 58.2 4.0 2.3 2360 398
9b Mono SC,12 50 nd nd ns ns ns
mean 14.9 40.1 55.1 8.4 6.2 1600.4 538
SD 16.6 6.5 3.9 6.2 1565.7 112.9
# Last visit uses data obtained at the last visit for each patient : this may be at 12 months, 6 months or before this time. Mean values include patients who
completed and who did not complete 12 months of treatment; the latter patients are shown in italics. Statistics are not used from this Table as the pre-planned
analysis was on longitudinal data shown in the figures.
Comb (Combination) = DFP + DFO. Mono (monotherapy) = DFO alone. SD = standard deviation of the mean. nd = not done. SC = subcutaneous, IV = intravenous.
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Seven patients completed at least close to 12 months with
combination and 4 patients with DFO monotherapy.
Some patients had both increases and decreases in
DFO dosing, depending on ferritin trends and AEs. In
the combination arm; DFP was halved and subsequently
interrupted in patient 2a due to nausea and vomiting; in
patient 3a, DFP was interrupted due to cardiovascular
instability (hypotension) and HF at week 4–6; in patient
7, DFP was interrupted due to leucopenia and subse-
quently stopped at week 19 due to abdominal pain; pa-
tient 9a, DFP and DFO was interrupted (week 9–10) due
to atrial fibrillation. DFO dosing was decreased in pa-
tients 3a, 7a & 11a due to falling ferritin trends with
additional mild retinal toxicity in patient 3a. In the DFO
monotherapy arm, DFO was dose reduced due to falling
serum ferritins in patients 5b, 6b and 8b and the doselater increased in patient 8 as serum ferritin increased.
In the DFO monotherapy arm, placebo was interrupted
in patient 3b at week 7 due to heart failure.
In total, 17 SAEs were reported with combination
(7 ‘at least remotely related’ to treatment) and 6 with DFO
monotherapy (2 ‘at least remotely related’ to treatment).
The use of the term ‘at least remotely related to’ is a sub-
jective assessment at the choice of the investigator if
he/she believes there may be a remote link between treat-
ment and the observed effect. Heart failure developed in 3
patients, one in the combination arm and 2 in the mono-
therapy arm. Heart failure (HF), in patient 3a receiving
combination improved with inotropic support and after
removing beta-blockers. HF deteriorated in patients 2b
and 3b who both received monotherapy, with death
resulting from HF. In patient 2b receiving monotherapy,
HF was associated with high fever, nausea and vomiting.
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atrial tachycardia and did not improve despite increasing
the DFO to 75 mg/kg. Other SAEs with combination arm
included high ALT (1), septic shock (1), retinal toxicity
(1), line infection (1), meningitis (1), hyperkalemia with
hyperglycemia (1), leucopenia (ANC =1.4) (1), atrial fibril-
lation (1), and urinary infection (1). Other SAEs in the
DFO monotherapy arm included pneumonia (1), HF (2),
atrial tachycardia (1), high ALT (1) and splenectomy (1).
Compliance and incomplete dosing
The mean missed days of DFO doses per month were
3.02 in the combination arm and 2.82 in the monother-
apy arm. The mean missed doses of DFP were 6.02 per
month and 4.51 for placebo in the monotherapy arm.
The mean returned pills per month with DFP were 36.3
and 30.0 for monotherapy placebo pills. From missed
doses, it can be estimated that 79% of the prescribed
DFP was taken throughout the study, compared with
85% of placebo pills in the monotherapy arm. Returned
tablets were slightly higher in the DFP group. However
patients on DFP or placebo remembered to return tab-
lets on only 59% and 66% of occasions respectively, so
that the correlation of missed doses by interview with
returned tablets was poor (r = 0.13) unless only patients
who returned tablets on more than 80% of occasions
were included (r = 0.67). According to trial coordinator/
nurse assessments, missed dosing attributable to AEs oc-
curred on 5 assessments with DFP (nausea (3), neutro-
phil count (1), multiple SAEs (1)) and once with DFO
monotherapy. Missed DFO doses were similar in the
two arms, equivalent to 90% compliance with no clear
difference with IV or SC treatment. Partial dosing was
rare. The mean prescribed duration of infusion was only
14 h in the DFP arm and 15 h in the monotherapy arm.Figure 1 Baseline, 6 month and 12 month LVEF for each patient in D
mean LVEF increased from 49.9% to 55.2% at 6 months (n = 10) and to 58.3% a
at 6 months (n = 6) and to 56.9% at 12 months (n = 4). The improvements are s
difference between arms (p = 0.86 for treatment; p = 0.89 for the interaction).LVEF changes by CMR
Figure 1 shows the baseline, 6 month and 12 month LVEF
for each patient. Table 1 shows individual baseline and
Table 2 final values (clear boxes completed 12 months,
shaded completed 6 months). Figure 1 shows that with com-
bination therapy, mean LVEF increased from 49.9%
to 55.2% at 6 months (n = 10) and to 58.3% at 12 months
(n = 7). With DFO monotherapy, LVEF increased from
52.8% to 55.7% at 6 months (n = 6) and to 56.9% at
12 months (n = 4). Improvement in LVEF was significant in
both study arms at 6 and 12 months (p = 0.04), normalizing
ventricular function in 9/16 evaluable patients. There was
no statistical difference between study arms for treatment
(p = 0.86) or for the interaction (p = 0.89). In this context,
interaction tests the hypothesis that one group changed
more over time than the other, whereas the test for treat-
ment tests for a difference between groups at all times. Nei-
ther was significant. The 3 patients who developed heart
failure (3a-combination, 2b-monotherapy, 3b-monotherapy)
had the lowest baseline LVEF values. Two of these also had
very low baseline T2* (2.4 and 2.7 ms) but the third had a
moderate T2* of 10.7 ms (Table 1).
Myocardial iron
Figure 2 shows baseline, 6 and 12 month myocardial T2*
values. Both treatment arms showed significant improve-
ment over time (p = 0.04). There was no difference
between groups (p = 0.65 for treatment; p = 0.48 for the
interaction) where tests for treatment, examine for differ-
ences between treatment groups at all times whereas tests
for interaction, examine whether one group changed more
over time than another. At 12 months the mean change
in myocardial T2* was nearly identical in the two groups
(1.9 ±1.6 ms with combination (n = 7) and 1.9 ±1.4 ms
with monotherapy (n = 4).FO monotherapy and DFP combination arms. With DFP combination,
t 12 months (n = 7): with monotherapy LVEF increased from 52.8% to 55.7%
ignificant over time in both arms (p = 0.04) but without significant
Figure 2 Baseline, 6 and 12 month myocardial T2* values with DFO monotherapy and DFP combination are shown. Myocardial T2*
improved in both arms (p = 0.04), with no significant difference between treatments (p = 0.65 for treatment; p = 0.48 for the interaction): improvement with
DFP was by 1.5 ms at 6 months and by 1.9 ms at 12 months: with DFP monotherapy this was by 1.1 ms and 1.9 ms respectively.
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Atrial dysrhythmias and conduction disturbances were com-
mon in both treatment arms with no clear progression dur-
ing the study (other than described as SAEs) and no
difference between the two study arms. There were no stat-
istical or clinically significant differences in the 6-minute
walk distance (meters, m) in the combination group (base-
line 469 m, 6 months 462 m, 12 months 484 m) and the
monotherapy group baseline 466 m, 6 months 507 m,
12 months 610 m) and no obvious trends of improvement
or deterioration.
Liver iron (LIC)
Figure 3 shows LIC values at baseline, 6 months and
12 months. LIC time effect p-value was 0.76 and the
interaction p-value was 0.03. The interaction p-value of
0.03 in indicates that only DFP combination therapy
showed significant decrease over time. The interactionFigure 3 LIC values at baseline, 6 months and 12 months. There is a sig
At 6 months, there is reduction with DFP combination (from 13.91 ± 3.87 to 9.19
1.96 to 7.43 ± 2.44 mg/g dry wt. (n = 6). At 12 months, there is a reduction of 4.2
dry wt, n = 7) and a slight reduction with DFO monotherapy from 5.62 ± 2.2 tohere tests the hypothesis that one group changes more
over time than another and shows that LIC decreased
more with combination therapy than with monotherapy.
LIC declined 4.7 mg/g in patients completing 6 months
and 6.8 mg/g in patients completing 12 months of com-
bination therapy. LIC was unchanged in patients treated
with DFO monotherapy. The absence of patient follow-
up or high baseline LIC values in the DFO monotherapy
arm (none >12.4 mg/g dwt) could account for the lack
of a significant decrease although baseline LIC did not
differ statistically.
Ferritin
In Figure 4, the ferritin trends are shown (with the ex-
ception of 1 patient in the DFO monotherapy arm with
a baseline ferritin of 7,349 whose ferritin increased to
73,163 μg/L when heart failure developed). At baseline, a
higher proportion of patients had ferritin >2500 μg/L innificant decrease in LIC with DFP combination (p = 0.03 for the interaction).
± 3.91 (n = 9) and a slight increase with DFO monotherapy (from 6.27 ±
9 mg/g dry wt in DFP combination (from 16.1 ± 4.67 to 9.27 ± 3.61 mg/g
5.08 ± 3.18 mg/g dry wt (n = 4).
Figure 4 Baseline and 4 weekly ferritin values in DFP combination and DFO monotherapy arms for individual patients and mean
(bold). With DFP combination, there is a significant downward trend from a baseline of 3308 ± 678 μg/L to 2371 ± 701 μg/L at 6 months (n = 9).
Between baseline and 10–12 months, serum ferritin declined from 3601 ± 838 to 2132 ± 646 μg/L (n = 7). In the DFO monotherapy arm, there is a
small downward trend from a baseline of 1880 ± 691 μg/L to 1603 ± 636 μg/L at 6 months (n = 6). In 4 samples at baseline and at 12 months,
serum ferritin increased from 1613 ± 537 μg/L to 2018 ± 898 μg/L.
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Ferritin trends differed significantly between treatment
arms (p < 0.001 for the interaction), with a decrease in
ferritin with combination, but an increase with mono-
therapy, over time.
Safety markers
Other than transient neutropenia in patient 7a-
combination, no agranulocytosis was seen. An early in-
crease in serum creatinine in both study arms of approxi-
mately 30% was seen, although values remained within
normal limits and trends were not progressive. There was
no significant trend in ALT in either arm, although three
patients developed sudden increments in ALT (1 DFP, 2
DFO monotherapy). In patient 2a, this rise to 611 iu/L
was associated nausea and vomiting and was reported as
an AE. In the DFO monotherapy arm, patient 3b de-
veloped very high ferritin values (73,163) associated
with heart failure as a pre-terminal event. Patient 3b-
combination also developed a high ALT also as a pre-
terminal event with heart failure. Audiometry, showed
worsening change of ≥15 dB on two or more frequencies
in only one patient (5a-combination at week 52), which
was unilateral and associated with middle ear disease. Eye
assessment on patient 3a-combination showed changes
consistent with monotherapy induced toxicity requiring
DFO dose reduction.
Discussion
In this study, the intention of the clinicians was to im-
prove treatment either by a combining DFP with DFO
or by giving a more intensive DFO regime than prior to
the trial, achieved by randomisation to either treatment.
DFO was allowed up to 24 h/day and up to 60 mg/kg.
The actual dosing allowed clinician discretion, taking
into account the risks of DFO overdosing and thepracticalities of 24 h DFO IV. Although this study did
not recruit the pre-planned patient numbers, it provides
valuable information about chelation and response of
iron overloaded patients with decreased LV function.
This study clearly shows that DFO intensification with
or without DFP is effective in improving LVEF and myo-
cardial T2* in this severely affected group of patients.
LVEF improvements are less in both study arms than
previously reported either with continuous high dose IV
DFO monotherapy [4-6] or with combined therapy in
TM with established LV dysfunction [8]. This may be
because the T2* values in this study at baseline are ge-
nerally lower than in other reports. For example in a
retrospective study of 24 h IV DFO monotherapy for pa-
tients with heart failure, the baseline T2* was also low
but contained no patients with a T2* <5 ms [6], unlike
our study where patients with particularly low T2*
values <3 ms were included (Table 1).
Early identification of cardiac risk is key to outcome.
Overall, symptomatic heart failure developed in 3 pa-
tients, one treated with combination and 2 with DFO
monotherapy, one preceded by high fever, the other by
nausea, vomiting and arrhythmia. One patient in the
combination arm (3a-comb) died within a year of com-
ing off the study, while still on DFP. The numbers of pa-
tients entered are too small to conclude whether these
differences between treatments are significant however.
Recent work has shown that the lower the T2*, the
greater the risk of heart failure in the next 12 months
which increases as the T2* falls <20 ms, with a relative
risk of 159 for T2* <10 ms and of 268 for T2* <6 ms
[16]. The T2* technique was introduced to several of the
participating centres as part of this study, so that for
some patients the T2* was not known prior to the study
observations. It is likely that low very T2* values at pres-
entation affect outcome. One death occurred with
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died off-study while on combination (3a-Comb) had a
baseline T2* of only 2.7 ms. The other death (2b-mono-
therapy) had a baseline T2* of 10.7 ms and would be
predicted as relatively low risk [16] but the deterioration
was preceded by severe sepsis, a recognised risk factor
in iron overload. At the time of initiation of the study,
myocardial T2* was not available as standard of care in
all participating centres so that early recognition of
high-risk patients on the basis of myocardial T2* was
not possible and deterioration in LVEF was therefore the
main entry criterion. This selects a very high risk patient
group which is still a way in which patients present in
centres lacking access to regular myocardial T2* mea-
surement. The introduction of myocardial T2* to some
participating centres should help to identify high-risk
patients at an earlier point in the future.
With respect to other changes in iron measures, the
lack of significant ferritin and liver responses in the
DFO monotherapy arm contrasts with previous studies
using DFO intensification, possibly reflecting the rela-
tively low baseline LIC and ferritin in this arm. A further
important difference between this study and others
where LVEF and other improvements were more marked
using DFO monotherapy [6,17] is that 24 h treatment
was the norm in former studies whereas 24 h treatment
was the exception here. Other patient variables such as
patient selection, previous chelation history and rapidity
of treatment intensification are difficult to control for
between studies. The only other report using combined
therapy for LV dysfunction, an observational study [9],
used similar doses of DFP with discontinuous DFO in
the majority of cases. The improvement overall in LVEF
at 1 year, from 51% to 63% was greater than in either
arm of our study. Changes in ferritin were also greater
than in our study, though T2* changes were similar.
Poor compliance in our study is unlikely to be a major
factor, being close to 80% in the DFP combination arm.
The changes in LIC and ferritin in both arms are also
less than reported in non-randomized studies with DFO
monotherapy [6] or with combined therapy [9].
Tolerability of interventional therapies is better assessed
in prospective trials than with retrospective reports. This
study did not find significant new issues with tolerabi-
lity with combined therapy but a larger study would be
needed to elucidate whether for example the agranulo-
cytosis increased with intensive combined therapy. ALT
changes are previously reported with DFP monotherapy
and may also occur with HF. Serum creatinine values
showed an early increase of nearly 30% in both study arms
and this effect of chelation intensification is of interest
because early increments of similar magnitude have been
described with deferasirox [18]. Serum creatinine incre-
ments have also previously been described with patientscommencing DFO at standard doses [19,20] or with
intensification of IV DFO [21]. There are no previous re-
ports of serial creatinine measurements with DFP mono-
therapy or in combination with DFO.Conclusions
This study provides randomized prospective information
about the efficacy and tolerability of chelation therapies
in high-risk patients with reduced LV function, in a field
where randomized studies are in short supply [2,3]. In-
tensification of DFO therapy with or without a DFP
combination was effective at improving LV function and
myocardial T2*. No difference in response of these mea-
sures was demonstrable with the patient numbers stu-
died. While the study is underpowered to show the
intended planned difference in LVEF between treatment
arms, if a difference of >8.6% had been present there
was 80% power to detect this. Thus it is possible that a
difference of LVEF improvement between 5–8.6% exists
between treatment arms but the study was underpow-
ered to show this. The study does not add any major
safety issues in the use of combination under these cir-
cumstances so that the decision to add DFP to intensive
DFO should be made on a case by case basis, weighing
the potential benefits suggested by other studies in less
severely affected patients, against the small risk of agran-
ulocytosis with combination therapy. Although this is
the largest and only randomized study in patients with
LV decompensation, further prospective evaluation with
larger patient numbers is needed to identify optimal che-
lation management in these high-risk patients.
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